Literature DB >> 23565132

Balancing the Efficacy and Safety of Vaccines in the Elderly.

Ian J Amanna1.   

Abstract

With advances in global health care, ageing populations are expected to grow worldwide throughout the 21st century. Increased lifespan is a testament to modern medical and social practices, but also presents a growing challenge to a system with limited resources. Elderly populations present specific concerns related to preventative health practices, especially vaccination. Although the power of vaccination is unquestionable in controlling infectious disease, immunosenescence can lead to reduced immune responses following immunization in the elderly, and increased morbidity and mortality. Further complicating this issue, some vaccines themselves may pose a substantial safety risk in the elderly when compared to younger counterparts. Though any health care intervention must balance risk and reward, safety and immunogenicity are often poorly characterized in older populations. This review explores several domestic and travel vaccines, examining what is known concerning efficacy and safety in the elderly, and considers future alternatives.

Entities:  

Keywords:  Vaccines; ageing; immunity; immunosenescence

Year:  2012        PMID: 23565132      PMCID: PMC3616444          DOI: 10.2174/1876326X01206010064

Source DB:  PubMed          Journal:  Open Longev Sci


  83 in total

1.  Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.

Authors:  Scott Kitchener
Journal:  Vaccine       Date:  2004-06-02       Impact factor: 3.641

2.  Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects.

Authors:  Robert B Couch; Patricia Winokur; Rebecca Brady; Robert Belshe; Wilbur H Chen; Thomas R Cate; Bryndis Sigurdardottir; Amy Hoeper; Irene L Graham; Robert Edelman; Fenhua He; Diane Nino; Jose Capellan; Frederick L Ruben
Journal:  Vaccine       Date:  2007-09-14       Impact factor: 3.641

3.  Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults.

Authors:  Daniel A Scott; Steven F Komjathy; Branda T Hu; Sherryl Baker; Lois A Supan; Carol A Monahan; William Gruber; George R Siber; Stephen P Lockhart
Journal:  Vaccine       Date:  2007-06-26       Impact factor: 3.641

4.  Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

Authors:  Lisa A Jackson; Kathleen M Neuzil; Moon H Nahm; Cynthia G Whitney; Onchee Yu; Jennifer C Nelson; Pat T Starkovich; Maya Dunstan; Barbara Carste; David K Shay; James Baggs; George M Carlone
Journal:  Vaccine       Date:  2007-03-12       Impact factor: 3.641

5.  Impact of influenza vaccination on seasonal mortality in the US elderly population.

Authors:  Lone Simonsen; Thomas A Reichert; Cecile Viboud; William C Blackwelder; Robert J Taylor; Mark A Miller
Journal:  Arch Intern Med       Date:  2005-02-14

6.  Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy.

Authors:  S Iannazzo
Journal:  J Prev Med Hyg       Date:  2011-03

Review 7.  New developments in flavivirus vaccines with special attention to yellow fever.

Authors:  Konstantin V Pugachev; Farshad Guirakhoo; Thomas P Monath
Journal:  Curr Opin Infect Dis       Date:  2005-10       Impact factor: 4.915

8.  Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.

Authors:  Douglas M Fleming; Pietro Crovari; Ulrich Wahn; Timo Klemola; Yechiel Schlesinger; Alexangros Langussis; Knut Øymar; Maria Luz Garcia; Alain Krygier; Herculano Costa; Ulrich Heininger; Jean-Louis Pregaldien; Sheau-Mei Cheng; Jonathan Skinner; Ahmad Razmpour; Melanie Saville; William C Gruber; Bruce Forrest
Journal:  Pediatr Infect Dis J       Date:  2006-10       Impact factor: 2.129

Review 9.  Yellow fever: the recurring plague.

Authors:  Oyewale Tomori
Journal:  Crit Rev Clin Lab Sci       Date:  2004       Impact factor: 6.250

10.  Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial.

Authors:  Takaya Maruyama; Osamu Taguchi; Michael S Niederman; John Morser; Hiroyasu Kobayashi; Tetsu Kobayashi; Corina D'Alessandro-Gabazza; Sei Nakayama; Kimiaki Nishikubo; Takashi Noguchi; Yoshiyuki Takei; Esteban C Gabazza
Journal:  BMJ       Date:  2010-03-08
View more
  6 in total

1.  Inflammatory responses to influenza vaccination at the extremes of age.

Authors:  Jacqueline U McDonald; Ziyun Zhong; Helen T Groves; John S Tregoning
Journal:  Immunology       Date:  2017-05-16       Impact factor: 7.397

Review 2.  Mega doses of retinol: A possible immunomodulation in Covid-19 illness in resource-limited settings.

Authors:  Ish K Midha; Nilesh Kumar; Amit Kumar; Taruna Madan
Journal:  Rev Med Virol       Date:  2020-12-31       Impact factor: 11.043

Review 3.  SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?

Authors:  Saborni Chakraborty; Vamsee Mallajosyula; Cristina M Tato; Gene S Tan; Taia T Wang
Journal:  Adv Drug Deliv Rev       Date:  2021-01-20       Impact factor: 17.873

4.  Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity.

Authors:  Cyrielle Fougeroux; Louise Goksøyr; Manja Idorn; Vladislav Soroka; Sebenzile K Myeni; Robert Dagil; Christoph M Janitzek; Max Søgaard; Kara-Lee Aves; Emma W Horsted; Sayit Mahmut Erdoğan; Tobias Gustavsson; Jerzy Dorosz; Stine Clemmensen; Laurits Fredsgaard; Susan Thrane; Elena E Vidal-Calvo; Paul Khalifé; Thomas M Hulen; Swati Choudhary; Michael Theisen; Susheel K Singh; Asier Garcia-Senosiain; Linda Van Oosten; Gorben Pijlman; Bettina Hierzberger; Tanja Domeyer; Blanka W Nalewajek; Anette Strøbæk; Magdalena Skrzypczak; Laura F Andersson; Søren Buus; Anette Stryhn Buus; Jan Pravsgaard Christensen; Tim J Dalebout; Kasper Iversen; Lene H Harritshøj; Benjamin Mordmüller; Henrik Ullum; Line S Reinert; Willem Adriaan de Jongh; Marjolein Kikkert; Søren R Paludan; Thor G Theander; Morten A Nielsen; Ali Salanti; Adam F Sander
Journal:  Nat Commun       Date:  2021-01-12       Impact factor: 14.919

Review 5.  Emerging concepts in the science of vaccine adjuvants.

Authors:  Bali Pulendran; Prabhu S Arunachalam; Derek T O'Hagan
Journal:  Nat Rev Drug Discov       Date:  2021-04-06       Impact factor: 84.694

Review 6.  Twenty Years of Progress Toward West Nile Virus Vaccine Development.

Authors:  Jaclyn A Kaiser; Alan D T Barrett
Journal:  Viruses       Date:  2019-09-05       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.